The Indian pharmaceutical sector is navigating potential supply chain disruptions stemming from the conflict in West Asia. Despite a customs duty waiver intended to ease financial pressures, concerns persist regarding the consistent availability of essential petrochemicals.
Industry experts have pointed out that while the duty exemption offers some cost mitigation, the primary challenges revolve around ensuring uninterrupted supply chains and the timely movement of materials. These logistical hurdles are critical for maintaining stable production within the pharmaceutical industry.
The government’s intervention through the customs duty waiver is aimed at stabilizing the supply of key materials and reducing input costs for critical sectors. However, the effectiveness of this measure is contingent on resolving the broader supply chain vulnerabilities exacerbated by the regional conflict.
About the Author
